TerminatedPhase 3

Efficacy of Retreatments With Intravitreal Bevacizumab

Stopped: Poor accrual

Mexico20 participantsStarted 2006-05

Plain-language summary

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

Who can participate

Age range60 Years – 95 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * \* Any visual acuity * OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid. * Active angiogram leakage Exclusion Criteria: * \* Basal Inflammatory disease * Endoftalmitis history * Lesions bigger than 5400 u or with scarring greater than 50% of lesion.

What they're measuring

Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram

Trial details

NCT IDNCT00406744

SponsorAsociación para Evitar la Ceguera en México

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2006-05

View on ClinicalTrials.gov More Age Related Macular Degeneration trials